Total raised
$2.5M
Last: Convertible Debt 2021-11
Stage
Seed
Founded
2017
Headcount
4
HQ
Bnei Brak
Sector
Health Tech & Life Sciences
About
EPM develops prescription medicine derived from synthetic cannabinoid acids to address unmet patient needs.
The company has created a pipeline that includes the discovery of 14 protected synthetic molecules, including eight novel structures and production process intellectual property.
Currently, EPM's focus is on two main therapeutic conditions: metabolic disorders (Prader-Willi syndrome) and inflammatory skin disease (psoriasis).
Funding history · 4 rounds · $2.5M total
2021-11
Convertible Debt
$100K
2021-05
Convertible Debt
$400K
2021-03
Convertible Debt
$1.0M
2020-11
Convertible Debt
$1.0M
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsHerbalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
oral-drugsdrug-developmentmedical-cannabiscannabisrespiratorydrug-discoverygeneric-drugspharmaceuticalsinflammatory-diseasesmetabolic-disease